Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients With Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: Results From the Phase 3 UNITY-CLL Study-MedSci.cn

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients With Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: Results From the Phase 3 UNITY-CLL Study

[Anonymous]

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021; 19 (1): 16

科室
- - 订阅+
  - 更多科室
工具
服务